DK3463422T3 - Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser - Google Patents

Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser Download PDF

Info

Publication number
DK3463422T3
DK3463422T3 DK17805843.4T DK17805843T DK3463422T3 DK 3463422 T3 DK3463422 T3 DK 3463422T3 DK 17805843 T DK17805843 T DK 17805843T DK 3463422 T3 DK3463422 T3 DK 3463422T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
metabolic disorders
treating metabolic
treating
Prior art date
Application number
DK17805843.4T
Other languages
Danish (da)
English (en)
Inventor
Hongli Liu
Original Assignee
Shanghai Hep Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co Ltd filed Critical Shanghai Hep Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3463422T3 publication Critical patent/DK3463422T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK17805843.4T 2016-05-30 2017-05-31 Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser DK3463422T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (1)

Publication Number Publication Date
DK3463422T3 true DK3463422T3 (da) 2024-07-22

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17805843.4T DK3463422T3 (da) 2016-05-30 2017-05-31 Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser

Country Status (10)

Country Link
US (2) US11633454B2 (enExample)
EP (1) EP3463422B1 (enExample)
JP (1) JP7684788B2 (enExample)
KR (1) KR102627084B1 (enExample)
CN (1) CN109310737B (enExample)
AU (1) AU2017274094B2 (enExample)
CA (1) CA3026140A1 (enExample)
DK (1) DK3463422T3 (enExample)
ES (1) ES2979305T3 (enExample)
WO (1) WO2017206898A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN104130316B (zh) * 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
US10413585B2 (en) * 2012-11-12 2019-09-17 Ruprecht-Karls-Universität Heidelberg Lipopeptides for use in treating liver diseases and cardiovascular diseases
MX383664B (es) * 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
ES2922883T3 (es) 2014-10-07 2022-09-21 Myr Gmbh Tratamiento combinado de la infección por VHB y VHD
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv

Also Published As

Publication number Publication date
US11633454B2 (en) 2023-04-25
AU2017274094A1 (en) 2019-02-14
US20230414706A1 (en) 2023-12-28
ES2979305T3 (es) 2024-09-25
JP7684788B2 (ja) 2025-05-28
KR20190015392A (ko) 2019-02-13
EP3463422A4 (en) 2020-02-26
CA3026140A1 (en) 2017-12-07
KR102627084B1 (ko) 2024-01-19
EP3463422B1 (en) 2024-05-22
WO2017206898A1 (en) 2017-12-07
CN109310737A (zh) 2019-02-05
US20200323951A1 (en) 2020-10-15
CN109310737B (zh) 2023-05-05
JP2019520341A (ja) 2019-07-18
AU2017274094B2 (en) 2020-09-10
EP3463422A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
IL287952A (en) Compositions and methods for non-myeloablative conditioning
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3206497T3 (da) Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3519572T5 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3347015T3 (da) Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser
DK3524255T3 (da) Sammensætning til behandling af acne
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3481856T3 (da) Materialer og metoder til behandling af smerterelaterede lidelser
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme